Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Renal Cell 26Kidney Neoplasms 21Melanoma 20Leukemia 17Leukemia, Myeloid, Chronic-Phase 15Multiple Myeloma 12Lymphoma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms, Plasma Cell 8Lymphoma, Follicular 7Pancreatic Neoplasms 6Waldenstrom Macroglobulinemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Neoplasms 4Lymphoma, Mantle-Cell 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4Urinary Bladder Neoplasms 3Primary Myelofibrosis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × Interferon-alpha × Clear all
NCT00019474 2018-09-14

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Montefiore Medical Center

Phase 2 Completed
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT00006006 2013-02-11

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

National Cancer Institute (NCI)

Phase 2 Completed
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00250796 2010-01-07

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

University of New Mexico

Phase 2 Completed
12 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡